

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: GP2/18 - Detection of Monoclonal Components

Dead line: 21.09.2018

Key: >>> ... marks correct (expected) result

> ... marks conditionally correct (acceptable) result

± ... marks the result not evaluated

N ... number of the results

Nrel ... relative number of the results

Test

Sample	Group	N	Result	N _{rel}	
(246) Gammopathies (typisation)					
A	(12) Beckman Coulter	>>>	1 IgA-kappa	1,1 %	
	(34) Sebia	>>>	54 IgA-kappa	59 %	
		>>>	3 IgA-kappa; kappa-free	3,3 %	
			1 IgA-kappa; kappa-free; lambda-free	1,1 %	
	(49) BioVendor	>>>	1 IgA-kappa	1,1 %	
	(91) Binding Site	>>>	1 IgA-kappa	1,1 %	
	(100) Helena	>>>	1 IgA-kappa	1,1 %	
	(213) Interlab Srl	>>>	29 IgA-kappa	32 %	
		>>>	1 IgA-kappa; kappa-free	1,1 %	
	----- Total per sample: n = 92 -----		Success: 99 %		
	B	(12) Beckman Coulter	>>>	1 kappa-free	1,1 %
(34) Sebia		>>>	2 Not specified	2,2 %	
		>>>	9 kappa	9,8 %	
		>>>	14 kappa; kappa-free	15 %	
		>>>	33 kappa-free	36 %	
(49) BioVendor		>>>	1 kappa; kappa-free	1,1 %	
(91) Binding Site		>>>	1 kappa	1,1 %	
(100) Helena		>>>	1 kappa	1,1 %	
(213) Interlab Srl		>>>	4 Not specified	4,3 %	
		>>>	6 kappa	6,5 %	
		>>>	6 kappa; kappa-free	6,5 %	
	>>>	14 kappa-free	15 %		
----- Total per sample: n = 92 -----		Success: 93 %			
Total success: 92 %					